Abstract: A computing device, includes one or more processors, configured to receive first data corresponding to a first radiofrequency signal received from a first wireless communication device, and second data corresponding to a second radiofrequency signal received from a second wireless communication device; select either the first wireless communication device or the second wireless communication device as a repeater device based on the first data or the second data according to one or more repeater selection criteria; instruct a transceiver to send a third radiofrequency signal to the repeater device, wherein the third radiofrequency signal comprises third data and an instruction for the repeater device to repeat the third data to the third wireless communication device.

Abstract: The embodiments described herein are directed to computer-implemented visual query matching methods and systems for implementing thereof. An example method includes storing first query data including queries associated with a first set of users, wherein each query includes selected criteria from multiple query criteria and first filter data for the multiple query criteria: storing second query data including metadata and queries associated with a second set of users, wherein each query includes selected criteria from the multiple query criteria and second filter data for the multiple query criteria: determining, by a processor, matching users from the second set of users for a first user of the first set of users; and providing, by the processor to the first user, a dashboard display including a matrix of the matching users.

Abstract: The present disclosure relates to methods of treating diseases or disorders associated with LGL and/or NK cells, methods of reducing or depleting LGL and/or NK cells, and methods of inducing ADCC activity using antibodies that bind to a cell surface protein on LGL and/or NK cells and comprise enhanced ADCC activity. The present invention also relates to a method of depleting or reducing the numbers of large granular lymphocytes and natural killer cells in a human subject upon administration of CD94 or CD57 or NKG2A binding molecule that consists of a part that specifically binds to the CD94 or CD57 or NKG2A receptors and an immunoglobulin Fc part. In a specific embodiment, a method of the invention depletes or reduces the number of large granular lymphocytes and natural killer cells in spleen, blood, bone marrow, joints, or other tissues.

Abstract: Clamping apparatus is provided for clamping together two or more items in use. The clamping apparatus includes at least one clamp member that can be moved between clamped and undamped positions in use, and joining means for joining together the at least one clamp member and the two or more items in user. The joining means have first engagement means for engagement of the joining means to the at least one clamp member and at least second engagement means for allowing engagement between the joining means and at least one of the items being clamped in user. The joining means has a first edge or side, and a second edge or side different to and a spaced distance apart from the first edge or side. The first engagement means are provided on or associated with the first edge or side and the at least second engagement means are provided on or associated with the second edge or side.

Abstract: Anti-PVRIG, anti-TIGIT, and anti-PVRIG/anti-TIGIT bispecific antibodies are provided, as well as compositions, and methods of using the antibodies for the treatment of cancer.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.

Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7 and H9, such as, for example all of H1, H2, H3, and H5 subtypes, and methods and means for making such antibodies. More specifically, the invention concerns antibodies capable of neutralizing more than one, preferably all, isolates of an influenza A virus subtype.